Nanoparticles delivering an sPLA2 blocker for knee osteoarthritis
Treating knee osteoarthritis by sPLA2 inhibitor-loaded micellar nanoparticles
This project uses tiny, drug-filled nanoparticles to deliver an sPLA2-blocking medicine into the knee to reduce inflammation and slow knee osteoarthritis in people with painful knee OA.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11516244 on NIH RePORTER |
What this research studies
From a patient's point of view, researchers are developing micellar nanoparticles that carry a drug to block the enzyme sPLA2, which is linked to joint inflammation in osteoarthritis. They will test how well these nanoparticles stay in the joint, penetrate cartilage, and reduce inflammatory signals using lab and animal experiments and tissue analyses. The team plans experiments to measure cartilage protection, joint inflammation, and drug distribution after local delivery to the knee. Findings will guide whether this delivery approach could move toward human testing or sample-based studies.
Who could benefit from this research
Good fit: People with symptomatic knee osteoarthritis, especially those with early to moderate disease and inflammation-driven symptoms, would be most likely to qualify for a treatment like this.
Not a fit: People with end-stage, severely damaged knees or whose pain is unrelated to joint inflammation are less likely to benefit from this approach.
Why it matters
Potential benefit: If successful, this approach could lower joint inflammation, slow cartilage damage, reduce knee pain, and delay or decrease the need for knee replacement surgery.
How similar studies have performed: Previous anti-inflammatory drugs have shown limited success in slowing OA in patients, and targeting sPLA2 with nanoparticle delivery is a relatively new and largely preclinical approach.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Cheng, Zhiliang — University of Pennsylvania
- Study coordinator: Cheng, Zhiliang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.